Clinical Trials Browser

Hormone Sensitive Prostate Cancer

HER2 Negative Breast Cancer

Breast Neoplasms, Sexual Dysfunctions, Psychological

PSA Level Greater Than Two

Stage I Prostate Adenocarcinoma AJCC v7

Prostatic Neoplasms

Prostate Adenocarcinoma

Prostatic Neoplasms

Prostatic Neoplasms

Prostate Adenocarcinoma

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Salivary Gland Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms, Patient Compliance

Salivary Gland Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

HER2-positive Breast Cancer

Prostatic Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Castration-resistant Prostate Cancer Patients with Oligometastases

Carcinoma, Lobular

Prostatic Neoplasms

Breast Neoplasms

Prostatic Neoplasms, Sarcopenia

Prostatic Neoplasms

Breast Neoplasms

Clinical Trials

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

SELECT

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

DIVINE

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

THUNDER

CARABELA

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

ARCH

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

PETREMAC

CASPAR

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

NePtune

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

RWE About QOL and Compliance of Patients With OFS in China

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

STEEL

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

The COSMYC Trial (COmbined Suppression of MYC)

FASCINATE-N

CARLHA-2

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

HypoElect

FACILE

PCS III

Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients

The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

PCS IX

ROSALINE

Micro RNAs to Predict Response to Androgen Deprivation Therapy

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

NEOLETRIB